A phase I study of Lapatinib (GW572016) and topotecan in patients with solid tumors.

被引：0
|
作者：
Erlichman, C
Adjei, AA
Joy, ME
Rubin, SD
Friedman, RA
Ames, MM
Reid, JM
Molina, JR
机构：
[1] Mayo Clin, Rochester, MN USA
[2] GlaxoSmithKline Oncol, Res Triangle Pk, NC USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8994S / 8994S
页数：1
相关论文
共 50 条
  • [31] A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009).
    Jones, SF
    Hainsworth, JD
    Spigel, DR
    Peacock, NW
    Willcutt, NT
    Pandite, LN
    Versola, PMJ
    Koch, KM
    Greco, F
    Burris, HA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 147S - 147S
  • [32] Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOL-FOX41 in patients with solid tumors.
    Lakhai, WS
    Beijnen, JH
    Den Boer, SS
    Westermann, AM
    Versola, M
    Koch, K
    Ho, P
    Pandite, L
    Richel, DJ
    Schellens, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 138S - 138S
  • [33] S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer
    Iqbal, S.
    Goldman, B.
    Lenz, H. J.
    Fenoglio-Preiser, C. M.
    Blanke, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Lapatinib (GW572016): A novel approach to inhibit ErbB1/ErbB2
    不详
    TOXICOLOGIC PATHOLOGY, 2005, 33 (07) : 813 - 814
  • [35] Lapatinib (GW572016): a novel approach to inhibit ErbB1/ErbB2
    Stein, SH
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (09) : 697 - 697
  • [36] A phase I study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
    Cash, Thomas
    Jonus, Hunter C.
    Tsvetkova, Maya
    Beumer, Jan Hendrik
    Lee, Jasmine Y.
    Henry, Curtis
    Aguilera, Dolly
    Harvey, R. Donald
    Goldsmith, Kelly C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    C.-P. Schneider
    U. Merkel
    U. Grübner
    R. Kath
    K. Höffken
    A. Hoffmann
    Journal of Cancer Research and Clinical Oncology, 2002, 128 : 313 - 318
  • [38] A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing reimens
    Blackwell, Kimberly
    Kaplan, Edward H.
    Franco, Sandra X.
    Marcom, P. Kelly
    Maleski, Janet
    Sorensen, Mel
    Berger, Mark S.
    ANNALS OF ONCOLOGY, 2004, 15 : 27 - 27
  • [39] Phase I study of pazopanib and ixabepilone in patients with solid tumors.
    Ganesan, Chitra
    Obulareddy, J.
    Bliss, Robin L.
    Dudek, Arkadiusz Z.
    CANCER RESEARCH, 2013, 73 (08)
  • [40] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    Burris, HA
    Hurwitz, HI
    Dees, EC
    Dowlati, A
    Blackwell, KL
    O'Neil, B
    Marcom, PK
    Ellis, MJ
    Overmoyer, B
    Jones, SF
    Harris, JL
    Smith, DA
    Koch, KM
    Stead, A
    Mangum, S
    Spector, NL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5305 - 5313
12345